ACE-031, also called ramatercept, is a decoy receptor built to soak up myostatin — the body's brake on muscle growth. Unlike most compounds sold online for muscle, it genuinely reached human trials. Those trials are also why it no longer exists as a drug program.
It is not a peptide. ACE-031 is the outer section of the activin type IIB receptor fused to an antibody tail, a protein of roughly 58 kilodaltons. Anything above 40 amino acids is a protein under 21 CFR 600.3(h)(6), which makes it a biological product rather than a compoundable peptide.
A single exposure did grow muscle in healthy people. In 48 healthy postmenopausal women, total lean mass rose 3.3% and thigh muscle volume rose 5.1% by day 29 at the highest exposure studied.
Both repeat-dosing trials in Duchenne muscular dystrophy were terminated. ClinicalTrials.gov records the reason in the sponsor's own words: "Based on preliminary safety data." The published report names nosebleeds and telangiectasias, small dilated blood vessels in the skin.
The reason is mechanical, not bad luck. This style of trap also catches BMP9, a signal that keeps blood vessels stable. A 2021 study confirmed it by building a redesigned trap that grabs the muscle-limiting ligands but leaves BMP9 alone, and the two versions behaved differently in a blood-vessel assay.
The pathway did produce approved medicines — for other things. Two related receptor-trap biologics are FDA-approved: one for anemia, one for pulmonary arterial hypertension. Neither is approved for building muscle.
Nothing sold as ACE-031 has been shown to be ACE-031. An anti-doping laboratory analyzed 14 black-market products in 2025. Twelve contained a receptor protein, but none contained the fusion protein from the trials.
Status in 2026: no approved product anywhere, development discontinued, and prohibited in sport at all times under WADA class S4.3.
This PeptIQ.io guide was written on November 20, 2026 from PubMed, ClinicalTrials.gov, FDA approval records and product labels, the Code of Federal Regulations and the WADA 2026 Prohibited List. It contains no dosing information.
Talk to a licensed clinician before using anything sold as ACE-031.
What Is ACE-031?
ACE-031 is a ligand trap. Cells sense myostatin and its relatives through a surface receptor called activin receptor type IIB, usually shortened to ActRIIB. Acceleron Pharma took the external, signal-catching part of that receptor and fused it to the Fc tail of a human IgG1 antibody. The result circulates in the blood like a free-floating decoy: ligands that would have docked on muscle bind the decoy instead and are carried away.
The antibody tail is not decoration. It is what gives the molecule a long residence time in the body — the Phase 1 study measured a half-life of roughly ten to fifteen days — and it is also the structural feature that tells a genuine product apart from an imitation, as the laboratory work below shows.
PeptIQ.io / ACE-031 / 01
A decoy receptor that catches more than it was aimed at.
ACE-031 is the outer part of the activin type IIB receptor welded to an antibody tail. Floating in the blood, it soaks up the signals that would otherwise dock on muscle. Selectivity is the whole story.
Intended
Myostatin (GDF-8)
The intended target. Removing it from circulation releases the brake on muscle growth.
Intended
Activin A
A related ligand for the same receptor. Trapping it adds to the muscle effect.
Off-target
BMP9
A ligand that helps keep blood vessels stable. The decoy catches this one too, and that is the problem.
Not a peptide
Roughly 58 kilodaltons.
Receptor fragment plus an IgG1 tail, far above the 40-amino-acid line that separates peptides from proteins in 21 CFR 600.3(h)(6).
That makes it a biological product, so it cannot be a compounded peptide at all.
Evidence, not marketing.Nov 2026
Sources: Attie et al., Muscle & Nerve 2013 (PubMed 23169607); Cadena et al., J Appl Physiol 2010 (PubMed 20466801); Li et al., J Clin Invest 2021 (PubMed 33586684), which showed a redesigned heterodimeric trap that binds muscle-limiting ligands but not BMP9. Simplified for education; not treatment advice.
Two consequences follow from the design, and both matter more than any marketing claim:
It is a protein, not a peptide. The main compound runs at about 58 kilodaltons on a gel. FDA's definition in 21 CFR 600.3(h)(6) puts anything with more than 40 amino acids in the protein category, and proteins are regulated as biological products. That is the same reason IGF-1 LR3 and follistatin 344 cannot appear on the federal peptide compounding lists: the category does not apply to them.
A trap is only as good as its selectivity. A decoy receptor catches whatever that receptor normally binds. ActRIIB binds myostatin and activins, which is the point, but it also binds BMP9, which turned out not to be.
Why Myostatin Is the Target
Myostatin, originally named GDF-8, is made almost exclusively in skeletal muscle and acts as a continuous brake on its growth. The 1997 paper that described it reported mice bred without the gene whose individual muscles weighed two to three times those of normal animals. Nothing else in muscle biology produces an effect that large from a single change, which is why blocking myostatin has been pursued for nearly thirty years.
Several strategies target the same brake from different angles. Antibodies neutralize myostatin directly. Follistatin binds it as a natural sequestering protein. ACE-031 intercepts it at the receptor. PeptIQ.io covers the antibody approach in the bimagrumab and apitegromab guide, and the research wiki holds a 2022 review of myostatin-inhibiting strategies.
The animal results are not in question. A 2010 study in mice found that four weeks of ACE-031 raised body weight by about 16% over controls, with hindlimb muscle weights up by roughly a quarter to a half and fiber size increased in both slow and fast fiber types. In 2026 — fifteen years after human development stopped — the original scientists published a 14-week study in common marmosets showing higher lean mass, larger biceps fibers of both types, and more absolute and specific force from an isolated leg muscle tested outside the body. That paper's conflict-of-interest statement notes that the company holding the patent "is no longer active."
What the Human Evidence Actually Shows
PeptIQ.io / ACE-031 / 02
The evidence runs out exactly where the market begins.
ACE-031 is one of the few muscle-building compounds sold online that genuinely reached human trials. Reading what those trials measured, and when they ended, is the whole exercise.
Mice
Four weeks of treatment raised body weight and grew every hindlimb muscle measured, across both fiber types.
Consistent
Marmosets
A 14-week primate study found higher lean mass, larger biceps fibers and more force from an isolated muscle. Published in 2026, fifteen years after human development stopped.
Supportive
Healthy adults, single exposure
Forty-eight healthy postmenopausal women, one injection each. At the highest exposure studied, total lean mass rose 3.3% and thigh muscle volume 5.1% by day 29.
Real but brief
Repeat use in patients
Two randomized trials in boys with Duchenne muscular dystrophy were both terminated on preliminary safety data. Muscle and walking trends favored treatment but were not statistically significant.
Stopped
Repeat use in healthy people
No published trial, in 2026 or ever. Nobody has studied what blocking this pathway long term does to someone who is not ill.
Untested
Evidence, not marketing.Nov 2026
Sources: Cadena et al., J Appl Physiol 2010 (PubMed 20466801); Cadena et al., PLoS One 2026 (PubMed 41686840); Attie et al., Muscle & Nerve 2013 (PubMed 23169607); Campbell et al., Muscle & Nerve 2017 (PubMed 27462804); ClinicalTrials.gov NCT00755638, NCT00952887, NCT01099761 and NCT01239758. Registry and PubMed searches run November 20, 2026.
Phase 1, healthy volunteers (2013). Forty-eight healthy postmenopausal women received a single injection of ACE-031 or placebo in a double-blind study. It was generally well tolerated, with injection-site redness among the adverse events. At the highest exposure studied, total body lean mass measured by DXA rose a statistically significant 3.3% and thigh muscle volume measured by MRI rose 5.1% by day 29. Serum markers also suggested effects on bone and fat metabolism. This is the strongest human efficacy evidence that exists for the compound, and it covers one injection and four weeks.
Phase 2, Duchenne muscular dystrophy. The program then moved to ambulatory boys with DMD in a randomized, double-blind, placebo-controlled ascending-dose trial, with safety as the primary objective. The published results report no serious or severe adverse events, and trends favoring treatment: maintenance of six-minute walk distance against a decline on placebo, increased lean body mass and bone mineral density, reduced fat mass. None of those trends reached statistical significance.
The trial stopped after the second dosing regimen. ClinicalTrials.gov lists four ACE-031 studies in total — two completed Phase 1 studies (NCT00755638, NCT00952887) and two Phase 2 studies in DMD, both marked terminated. The extension study's stated reason reads: "This study was terminated based on preliminary safety data."
Why Development Stopped
The published trial report names the specific findings that ended it: epistaxis (nosebleeds) and telangiectasias, the small dilated surface blood vessels that show through skin. The authors were explicit that these were non-muscle-related adverse events, and that they drove the decision to discontinue.
What makes this more than an isolated signal is that the mechanism was later pinned down. ActRIIB does not only bind muscle-limiting ligands; it also binds BMP9, which helps maintain blood-vessel stability. A broad ActRIIB decoy therefore removes BMP9 from circulation along with myostatin.
A 2021 Journal of Clinical Investigation study tested that explanation by engineering a different trap — a heterodimer pairing ActRIIB with a type I receptor domain. Binding measurements showed it sequestered the ligands known to inhibit muscle growth but not BMP9, and the two designs produced different effects on vessel outgrowth in a retinal assay. The redesigned version increased muscle mass and function in mice and in models of muscular dystrophy, ALS and disuse atrophy. In other words, the vascular problem was a property of the original trap's breadth, and fixing it required changing the molecule.
That is a critical point for anyone considering a product sold under the ACE-031 name. The safety signal was not an impurity or a manufacturing accident. It followed from how the trial compound was built, and nothing sold online has been redesigned.
Where This Pathway Did Succeed
The receptor-trap idea was not abandoned. Two closely related ActRII-Fc fusion proteins are FDA-approved today, and both show what the pathway is genuinely good for:
Luspatercept (Reblozyl), a modified ActRIIB-Fc, was approved under BLA 761136 on November 8, 2019. Its label describes an erythroid maturation agent for anemia in adults with beta thalassemia and with lower-risk myelodysplastic syndromes.
Sotatercept (Winrevair), an ActRIIA-Fc, was approved under BLA 761363 on March 26, 2024, as an activin signaling inhibitor for adults with pulmonary arterial hypertension, to improve exercise capacity and functional class and reduce the risk of clinical worsening.
Neither is approved for muscle growth, athletic performance or body composition. Both are prescription biologics given under specialist supervision, with their own labeled warnings. The honest summary of this family of drugs in 2026 is that activin-pathway traps became real medicines for blood and lung disease, while the muscle-building application stalled on safety and never came back.
What Was Actually in the Vials
PeptIQ.io / ACE-031 / 03
Fourteen products. None of them were ACE-031.
An anti-doping laboratory bought what the market sells under this name and ran it through gel electrophoresis, immunoblotting and mass spectrometry.
12 of 14
held a receptor protein. None held the trial compound.
The test
Antibodies against the receptor recognized twelve of the products, so a basic check would call them genuine.
0 of 14
actually contained ACE-031. All twelve held the plain full-length receptor, with no antibody tail fused to it.
Proof
an enzyme that cleaves antibody tails could not cut the products at all, and mass spectrometry agreed.
Status in 2026
No approved ACE-031 product anywhere, development discontinued, and prohibited in sport at all times under WADA class S4.3.
Evidence, not marketing.Nov 2026
Source: Reichel, Filip, Gmeiner and Thevis, Drug Testing and Analysis 2025 (PubMed 40312924). The authors also reported many additional unidentified proteins alongside the main compound, and said administering the products to people was not ethically justifiable, so their recovery study used rats.
In 2025, chemists at an accredited anti-doping laboratory published an analysis of 14 products sold on the black market as ACE-031. The result is the single most practical finding in this guide.
Twelve of the fourteen contained a protein that antibodies against the activin receptor recognized — so a basic test would mark them authentic. Deeper analysis showed something else. All twelve contained the full-length human activin receptor IIB protein instead of ACE-031. The fusion was missing: an enzyme called IdeS, which cleaves antibody Fc regions, could not cut the products at all, and mass spectrometry confirmed the identification. The products also carried numerous additional proteins alongside the main compound.
So on the evidence available, the count of tested products that actually contained the trial compound is zero. Whatever those vials do in a human body, it is not what the Phase 1 trial measured. The authors also noted that giving black-market products to people was not ethically justifiable, so their detection-window study was done in rats.
Anyone who has read our guide on how to vet a peptide source will recognize the pattern: a certificate of analysis built on a test that cannot distinguish the real molecule from a cheaper protein tells a buyer nothing.
Regulatory Status in 2026
No approved product. There is no FDA-approved ACE-031 or ramatercept product for any indication, and the clinical program was discontinued more than a decade ago.
It cannot be a compounded peptide. As a fusion protein well above the 40-amino-acid threshold, ACE-031 is a biological product under 21 CFR 600.3(h)(6). It is therefore absent from Appendix A of the October 30, 2026 HHS enforcement-discretion policy on 503A peptide compounding, and from FDA's peptide bulk-substance categories, for a structural reason rather than a policy judgment.
"Research use only" is not a legal route to use. Material sold with that label is not an approved medicine and has not been evaluated for human use.
Prohibited in sport at all times. The WADA 2026 Prohibited List bans myostatin inhibitors, including myostatin-binding proteins, under class S4.3, in and out of competition. The 2025 laboratory paper describes ACE-031 as banned under that chapter, and anti-doping laboratories have published validated blood tests for activin-receptor Fc fusion proteins.
For a general picture of how federal rules sort these compounds, see our guide to the 503A and 503B sourcing landscape. Readers comparing legitimate clinical routes for muscle and metabolic concerns can also review the physician-directed services listed at meds.you, which is referenced here for information only.
Safety Questions to Raise With a Clinician
If you are considering anything in this class, these are the questions worth bringing to a licensed clinician, and they are deliberately not answerable from a vendor page:
Bleeding and blood vessels. Nosebleeds and telangiectasias ended the clinical program. What is your personal risk, and what would you watch for?
Anything that affects bleeding. Prescription anticoagulants, antiplatelet drugs and some supplements act on the same system.
Blood counts and blood pressure. Related approved traps in this family carry labeled effects on red cell production and on pulmonary vasculature, and are monitored with lab work.
Long-term unknowns. The longest human exposure on record is a short, repeat-dose trial in children with a progressive disease that was stopped early. No one has data on healthy adults using this pathway for months or years.
Identity of the product. Published testing found that products sold under this name were not the trial compound. There is no consumer-level test that resolves this.
Immune response. Injected foreign proteins can provoke antibodies against themselves, and in the worst case against the body's own equivalent.
How PeptIQ.io Helps
PeptIQ.io is a tracking and education platform, not a pharmacy or a clinic. For a compound like this one, the useful parts are the parts that help you read evidence and keep records:
The ACE-031 compound profile summarizes the mechanism, the trial record and the halted development status in one place.
The research wiki links the primary papers so you can open them yourself rather than taking a summary on faith.
PeptIQ AI answers questions about what a given study measured and what it did not, with the sources attached.
If you are working with a clinician on anything injectable, the logging tools keep a dated record of what you took and what you noticed, which is far more useful in an appointment than a recollection.
Talk to a Licensed Clinician
Nothing here is a recommendation to use ACE-031. The compound has no approved form, its only repeat-dose human trials were stopped early for a safety signal with a known mechanism, and the products sold under its name have been shown not to contain it. If muscle loss, weakness or recovery is a real concern for you, that is a conversation for a licensed clinician, who can look for a cause and discuss options that have been tested in people.
Frequently Asked Questions
Q: What is ACE-031?
A: ACE-031, also called ramatercept, is a soluble decoy receptor made from the outer part of the activin type IIB receptor fused to an antibody tail. It binds myostatin and related ligands before they reach muscle, releasing the brake on muscle growth. It was developed by Acceleron Pharma and is not approved anywhere.
Q: Does ACE-031 actually build muscle?
A: In its only trial in healthy people, a single injection raised total lean mass by 3.3% and thigh muscle volume by 5.1% at day 29 in 48 postmenopausal women. Animal studies show larger effects. There is no published evidence on repeated use in healthy adults, and no trial has shown that the muscle gained translates into better strength or function in people.
Q: Why was ACE-031 discontinued?
A: Both Phase 2 trials in Duchenne muscular dystrophy were terminated on preliminary safety data, specifically nosebleeds and telangiectasias. Later work showed that this style of broad receptor trap also removes BMP9, a ligand involved in blood-vessel stability, and that a redesigned trap sparing BMP9 behaves differently in vascular assays.
Q: Is ACE-031 FDA approved?
A: No. There is no approved ACE-031 product for any use. Because it is a fusion protein above the 40-amino-acid threshold in 21 CFR 600.3(h)(6), it is a biological product rather than a peptide, so it also cannot appear in Appendix A of the October 30, 2026 HHS peptide compounding policy.
Q: Is ACE-031 the same as luspatercept or sotatercept?
A: They are relatives, not the same. All three are activin-receptor Fc fusion proteins. Luspatercept (Reblozyl, approved November 2019) treats certain anemias and sotatercept (Winrevair, approved March 2024) treats pulmonary arterial hypertension. Neither is approved for muscle growth, and both are prescription biologics with their own monitoring requirements.
Q: Is ACE-031 banned in sport?
A: Yes. The WADA 2026 Prohibited List bans myostatin inhibitors, including myostatin-binding proteins, under class S4.3, at all times in and out of competition. Anti-doping laboratories have published validated methods for detecting activin-receptor Fc fusion proteins in blood.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83-90. PubMed 9139826
Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109(3):635-642. PubMed 20466801
Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423. PubMed 23169607
Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458-464. PubMed 27462804
Li J, Fredericks M, Cannell M, et al. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. 2021;131(4):e138634. PubMed 33586684
Cadena SM, Bogdanovich S, Khurana TS, et al. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset. PLoS One. 2026;21(2):e0342666. PubMed 41686840
Reichel C, Filip T, Gmeiner G, Thevis M. Gel electrophoretic detection of black market ACE-031. Drug Test Anal. 2025;17(10):1934-1946. PubMed 40312924
Martin L, Zouhiri N, Audran M, Marchand A. A validated, sensitive electrophoretic method for the detection of activin receptor type II-Fc fusion proteins in human blood. Drug Test Anal. 2018. PubMed 29499588
FDA. Drugs@FDA records and prescribing information for REBLOZYL (luspatercept, BLA 761136, approved November 8, 2019) and WINREVAIR (sotatercept, BLA 761363, approved March 26, 2024)
World Anti-Doping Agency. 2026 Prohibited List, class S4.3, in force January 1, 2026
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.